MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

  • MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress
  • He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”)
  • Bertagna also hinted at potential acquisitions by the company, attributing it to extensive efforts over the past couple of years to clean up its balance sheet
  • He noted that as MetAlert’s revenue per user continues to grow, its margins will increase, ultimately placing the company in a position to uplist

While appearing in an interview presented by Sequire Spotlight, and hosted by Carmel Fisher, MetAlert (OTC: MLRT) CEO Patrick Bertagna discussed the company’s recent progress and how well it is poised to enter the 2023 financial year. Of note was his optimism in the new products launched thus far, such as the patented GPS SmartSole, a hub for collecting and transmitting data to the cloud in real-time, and RoomMate, an alert system that detects and alerts caregivers about patient behaviors, without intruding into their privacy (https://ibn.fm/q8cML).

MetAlert, a developer of personal protective medical equipment and supplies and a pioneer in wearable GPS, human and asset tracking systems, has sought to offer viable solutions to individuals afflicted with Alzheimer’s, dementia, and autism (“ADA”). This commitment has informed its approach and the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.